Financial Performance - For the year ended December 31, 2024, the company reported revenue of RMB 257.2 million, a year-on-year increase of 146.0% compared to RMB 104.6 million in 2023[5]. - Gross profit for the same period was RMB 86.2 million, representing a significant increase of 486.8% from RMB 14.7 million in the previous year[5]. - The company recorded a pre-tax loss of RMB 647.1 million, a reduction of 36.8% from a loss of RMB 1,023.5 million in 2023[5]. - Adjusted net loss for the year was RMB 482.6 million, down 44.5% from RMB 869.1 million in the prior year[5]. - Basic and diluted loss per share improved to RMB 0.66 from RMB 1.06, reflecting a decrease of 37.7%[5]. - The company reported a net loss attributable to equity shareholders of RMB 642.4 million, down from RMB 1,012.2 million in the previous year, indicating improved financial performance[6]. - The company incurred a pre-tax loss of RMB 3,168,000 for 2024, a decrease from a loss of RMB 13,342,000 in 2023, showing an improvement of 76.3%[23]. - The company recorded a net loss of RMB 647.1 million for the year ending December 31, 2024, compared to a net loss of RMB 1,023.5 million in 2023, resulting in an adjusted net loss of RMB 482.6 million[105]. Revenue Growth - Total revenue for 2024 reached RMB 257,249,000, a significant increase from RMB 104,592,000 in 2023, representing a growth of 146.1%[18]. - Revenue from medical devices and accessories sales amounted to RMB 252,410,000, with service income contributing RMB 2,230,000[18]. - The total expected revenue from existing customer contracts as of December 31, 2024, is RMB 19,128,000, up from RMB 6,144,000 in 2023, indicating a growth of 211.5%[19]. - Revenue from external customers in China was RMB 153,725,000 in 2024, compared to RMB 83,385,000 in 2023, reflecting an increase of 84.1%[22]. - The geographical revenue breakdown shows that revenue from Europe increased to RMB 36,076,000 in 2024 from RMB 7,503,000 in 2023, a growth of 380.5%[22]. Cost Management - The company achieved a 42% reduction in free cash flow outflow, decreasing from RMB 670 million in 2023 to RMB 388 million in 2024[6]. - Sales and marketing expenses decreased by 12.8% to RMB 207.9 million for the year ended December 31, 2024, down from RMB 238.4 million for the year ended December 31, 2023, due to adjustments in sales strategy[96]. - Administrative expenses decreased by 56.3% to RMB 55.3 million for the year ended December 31, 2024, compared to RMB 126.4 million for the year ended December 31, 2023, primarily due to operational efficiency improvements[97]. - R&D expenses decreased by 45.8% from RMB 569.2 million for the year ended December 31, 2023, to RMB 308.7 million for the year ending December 31, 2024, due to a focus on products nearing commercialization and improved R&D efficiency[98]. - Total employee costs for the year ending December 31, 2024, were RMB 178.9 million, down from RMB 350.4 million in 2023, primarily due to a reduction in workforce[99]. Cash Flow and Liquidity - The company’s cash and cash equivalents increased to RMB 612.2 million in 2024 from RMB 507.7 million in 2023, reflecting better liquidity management[10]. - Free cash flow net outflow decreased by 42%, from RMB 670 million to RMB 388 million, indicating improved cash flow management[57]. - Cash and cash equivalents increased from RMB 507.7 million as of December 31, 2023, to RMB 612.2 million as of December 31, 2024, primarily due to H-share placement and effective debt financing[112]. Strategic Initiatives - The company continues to focus on sustainable business growth and operational efficiency, enhancing its competitive advantage in the industry through a multi-track layout and superior product performance[47]. - The company is leveraging advancements in core technologies and integration with new technologies like 5G and artificial intelligence to enhance its product offerings and expand into international markets[44]. - The company has established two R&D centers in Shanghai and Shenzhen, focusing on rapid response to clinical needs and promoting industry upgrades[84]. - The company plans to increase its marketing budget by 15% to enhance brand visibility and customer engagement[146]. - The company aims to continue its global strategy by building an innovative platform for medical robots and collaborating with top hospitals and research institutions[92]. Product Development and Innovation - The company has applied for a total of 1,333 patents globally, with 509 granted, including 338 in China and 171 overseas, enhancing its innovation capabilities[89]. - The R-ONE vascular interventional robot has been approved by NMPA and has successfully entered the Chinese market with two commercial installations[50]. - The company has established the largest remote surgery network globally, completing over 300 remote surgeries with a 100% success rate[53]. - The company is developing a "third-generation remote surgery" concept, integrating satellite technology for comprehensive global coverage[82]. - The company has successfully completed over 300 cases of 5G remote clinical surgeries globally, achieving a 100% success rate and setting 25 world records[66]. Market Expansion - The company is exploring potential acquisitions to strengthen its market position and expand its technological capabilities[145]. - The expansion into the European market is a key focus, with projected sales growth of 40% in that region over the next two years[145]. - The company has successfully navigated regulatory approvals, including certifications from ANVISA and NMPA, facilitating entry into new markets[144]. Corporate Governance - The company has complied with all applicable corporate governance codes and regulations during the reporting period[130]. - There were no significant investments, acquisitions, or disposals of subsidiaries, associates, or joint ventures during the reporting period[136]. - The company does not recommend the distribution of a final dividend for the reporting period[140].
微创机器人-B(02252) - 2024 - 年度业绩